Nature Medicine
11, 822 - 824 (2005)
doi:10.1038/nm0805-822
TZDs and diabetes: testing the watersClay F Semenkovich
The author is in the Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine, St. Louis, Missouri 63110, USA. csemenko@wustl.edu
The use of thiazolidinediones, drugs for type 2 diabetes that may also be useful for other chronic inflammatory disorders, is limited by fluid retention. Research in mice identifies a mechanism for this side effect and introduces a potential remedy (pages 861−866).
MORE ARTICLES LIKE THIS These links to content published by NPG are automatically generated.
|
